Transcytosis

Voyager Therapeutics Presents Data for Second-Generation, TRACER™-Generated Capsids and CNS Gene Therapy Programs Advancing Toward Clinical Trials at the ASGCT 27th Annual Meeting

Retrieved on: 
Mercoledì, Maggio 8, 2024
TRACER, Brain, Traffic barrier, Cell, Mouse, Neuron, Tropism, Machine learning, RNA, B cell, AAV, Voyager, IND, CNS, Alkaline phosphatase, Crab-eating macaque, Human, DNA, Therapy, Astrocyte, Gene, Society, ALS, Spinal cord, BBB, DSM-IV codes, Central nervous system, Messenger, Capsid, Transcytosis, NHP, ALPL, HEK293, Centrifuge, SOD1, Vaccine

LEXINGTON, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced the presentation of data related to its TRACER™ capsid discovery platform and TRACER-driven gene therapy programs at the American Society of Gene & Cell Therapy’s (ASGCT) 27th annual meeting.

Key Points: 
  • Voyager identified a highly conserved cell surface receptor that mediates enhanced brain tropism of the VCAP-101/102 engineered capsid class.
  • Voyager has advanced machine learning to predict production fitness of capsid variants with high accuracy, helping guide development of high-production-fit libraries.
  • Robust manufacturing processes are needed to remove empty and partially filled capsids from recombinant AAV (rAAV) drug product.
  • This cost-efficient cell line provides an AAV expression platform to produce drug candidates for neurological disorders.

Affinia Therapeutics to Present Data on Novel Cardiotropic and BBB-Penetrant AAV Capsids and Preclinical Efficacy and Safety in Genetic Cardiomyopathies and Sporadic ALS at the American Society of Gene & Cell Therapy 2024 Annual Meeting

Retrieved on: 
Lunedì, Aprile 22, 2024
DRG, Heart, Traffic barrier, Computational science, Safety, Abstract (summary), Tropism, Cardiac muscle, MD, Structure, Diagram, Cell, BAG3, AAV, Skeletal muscle, CNS, Senior, Synthetic media, Liver, Gene, Society, ALS, Ataxin-2, BBB, Toxicity, Central nervous system, Messenger, Generative, Transcytosis, Annual general meeting, Therapy, Vaccine

Affinia's novel capsids have favorable manufacturing yields and levels of preexisting population immunity.

Key Points: 
  • Affinia's novel capsids have favorable manufacturing yields and levels of preexisting population immunity.
  • "We are excited to unveil data on our next-generation bespoke capsids that demonstrate robust cardiac transduction while detargeting the liver and DRG.
  • One oral presentation showcases data from Affinia's novel, BBB-penetrant AAV capsid with a potential therapeutic application to sporadic ALS.
  • The first poster showcases data that confirm the novel cardiotropic AAV capsid's safety and therapeutic efficacy in an animal model of cardiac dysfunction with a potential therapeutic application in genetic cardiomyopathies.

Novel Diagnostic Imaging Platform to Monitor the Progression and Treatment of Metastatic Cancers presented via Hidden GEMS Program from One Million Solutions in Health

Retrieved on: 
Giovedì, Giugno 24, 2021
Branches of biology, Biology, Transcytosis, Scavenger receptor, A2 milk, Cytosis

Dr. Stephan T. Stern shares his work in this scientific presentation and licensing opportunity review which is spearheaded by One Million Solutions in Health.

Key Points: 
  • Dr. Stephan T. Stern shares his work in this scientific presentation and licensing opportunity review which is spearheaded by One Million Solutions in Health.
  • This licensing opportunity introduces a novel technology polymeric delivery platform that targets the lymphatic system through scavenger receptor A1 (SR-A1) mediated transcytosis.
  • In this next year through the Hidden GEMS Program, we will be reviewing 100's of new solutions and new scientific discoveries.
  • Through the Hidden GEMS Program, the Technology Evaluation Consortium from One Million Solutions in Health is dedicated to improving and accelerating life sciences R&D and health care outcomes.

Novel Diagnostic Imaging Platform to Monitor the Progression and Treatment of Metastatic Cancers presented via Hidden GEMS Program from One Million Solutions in Health

Retrieved on: 
Lunedì, Febbraio 1, 2021
Branches of biology, Biology, Transcytosis, Scavenger receptor, A2 milk, Cytosis

Dr. Stephan T. Stern shares his work in this scientific presentation and licensing opportunity review which is spearheaded by One Million Solutions in Health .

Key Points: 
  • Dr. Stephan T. Stern shares his work in this scientific presentation and licensing opportunity review which is spearheaded by One Million Solutions in Health .
  • This licensing opportunity introduces a novel technology polymeric delivery platform that targets the lymphatic system through scavenger receptor A1 (SR-A1) mediated transcytosis.
  • In this next year through the Hidden GEMS Program , we will be reviewing 100's of new solutions and new scientific discoveries.
  • Through the Hidden GEMS Program , the Technology Evaluation Consortium from One Million Solutions in Health is dedicated to improving and accelerating life sciences R&D and health care outcomes.

Applied Molecular Transport Announces Publication of Preclinical Data Demonstrating Potential of Novel Oral IL-10 Biologic Therapeutic (AMT-101) for Inflammatory Diseases in The Journal of Immunology

Retrieved on: 
Martedì, Novembre 10, 2020
Medical specialties, Branches of biology, Clinical medicine, Immunology, Interleukins, Cytokine, Transcytosis, Autoimmunity, Inflammation, Sjögren syndrome, Biological therapy for inflammatory bowel disease, Interleukin 18

IL-10 is a potent immunomodulatory cytokine with significant therapeutic potential in intestinal inflammatory diseases as well as in those associated with systemic inflammation.

Key Points: 
  • IL-10 is a potent immunomodulatory cytokine with significant therapeutic potential in intestinal inflammatory diseases as well as in those associated with systemic inflammation.
  • However, clinical utilization of IL-10 to treat inflammation and immune-dysregulation has been limited due to side effects associated with systemic administration.
  • Our technology platform is based on native, active vesicular transcytosis mechanisms to rapidly and efficiently traverse intestinal epithelial cells.
  • Applied Molecular Transport Inc. is a clinical-stage biopharmaceutical company leveraging its proprietary technology platform to design and develop a pipeline of novel oral biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases.

Ossianix to Present Preclinical Data Demonstrating Best-in-Class Blood Brain Barrier Delivery in Non-Human Primates by Single Domain VNAR Antibodies

Retrieved on: 
Lunedì, Novembre 9, 2020
Life sciences, Medical specialties, Biology, Immunology, Biotechnology, Glycoproteins, Immune system, Antibody, Monoclonal antibody, Single-domain antibody, Biopharmaceutical, Transcytosis

PHILADELPHIA and STEVENAGE, United Kingdom, Nov. 9, 2020 /PRNewswire/ --Ossianix, an antibody engineering company, todayannounced the results of a non-human primate study demonstrating best-in-class blood-brain barrier (BBB) delivery by single domain antibodies.

Key Points: 
  • PHILADELPHIA and STEVENAGE, United Kingdom, Nov. 9, 2020 /PRNewswire/ --Ossianix, an antibody engineering company, todayannounced the results of a non-human primate study demonstrating best-in-class blood-brain barrier (BBB) delivery by single domain antibodies.
  • Poor brain delivery is a major barrier in the development of biological therapeutics for neurologic diseases because they are too large to cross the BBB.
  • The VNAR shuttle is a single domain antibody derived from sharks that is significantly smaller than monoclonal antibodies used today as therapeutics.
  • Ossianix is an antibody engineering companythat utilizes single domain antibodies (VNAR) from the shark to develop novel biopharmaceuticals for a number of therapeutic areas including CNS.

Unlocking the Blood-Brain-Barrier: A new simple and innovative way of delivering therapeutics to brain

Retrieved on: 
Martedì, Ottobre 15, 2019
Branches of biology, Biology, Life sciences, Biotechnology, Applied genetics, Peptides, Blood–brain barrier, Central nervous system, Neurology, Transcytosis

Scientists have traditionally faced the problem that blood capillaries in the brain are not permeable to many drugs.

Key Points: 
  • Scientists have traditionally faced the problem that blood capillaries in the brain are not permeable to many drugs.
  • For example, currently, one form of delivery to the brain is to use modified viruses to bypass the BBB and deliver medication to the brain.
  • The new technological breakthrough for delivering genetic materials (as well as other therapeutics) to cells in the brain uses a modified peptide identified from a virus that targeted the brain capillaries.
  • The platform technology allows for minimally invasive and combination delivery of various drugs, peptides, and nucleic acid therapeutics to the brain and other organs.

BioArctic Strengthens its Blood-brain Barrier Technology Platform With World Leading Scientist Recruitment

Retrieved on: 
Giovedì, Maggio 23, 2019
Branches of biology, Life sciences, Biology, Neurology, Brain, Animal physiology, Blood–brain barrier, Central nervous system, Circulatory system, Biopharmaceutical, Antibody, Transcytosis

Through the recruitment of Dr. Freskgrd, BioArctic further strengthens its capabilities in the neuroscience therapeutic area, antibody engineering and blood-brain barrier competence.

Key Points: 
  • Through the recruitment of Dr. Freskgrd, BioArctic further strengthens its capabilities in the neuroscience therapeutic area, antibody engineering and blood-brain barrier competence.
  • Today, Dr. Freskgrd is one of the world's leading experts on mechanisms that increase the passage of biologic drugs across the blood-brain barrier.
  • In collaboration with Uppsala University, BioArctic is developing novel technologies to increase the passage of antibodies over the blood-brain barrier.
  • "That Per-Ola Freskgrd, a world leading scientist on technologies to facilitate the passage of biologics across the blood-brain barrier, now has chosen to join BioArctic is a recognition of the high quality research at BioArctic.

Global Gene Therapy Companies, Technologies, & Markets, 2018-2019 & 2028: Focus on Genetic Disorders, Cancer, Neurological Disorders, Cardiovascular Disorders, & Viral Infections

Retrieved on: 
Martedì, Maggio 21, 2019
Branches of biology, Organ systems, Nervous system, Neurology, Central nervous system, Neuroscience, Animal physiology, Blood–brain barrier, Brain, Nanoparticles for drug delivery to the brain, Transcytosis

The delivery of drugs to central nervous system (CNS) is a challenge in the treatment of neurological disorders.

Key Points: 
  • The delivery of drugs to central nervous system (CNS) is a challenge in the treatment of neurological disorders.
  • The major challenge to CNS drug delivery is the blood-brain barrier (BBB), which limits the access of drugs to the brain substance.
  • Advances in understanding of the cell biology of the BBB have opened new avenues and possibilities for improved drug delivery to the CNS.
  • A number of cell and gene therapy companies with products in development for CNS disorders are included.